ifosfamide has been researched along with carfilzomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anampa-Guzmán, A; Block, A; Darrall, A; DeMarco, J; Ghione, P; Groman, A; Hernandez-Ilizaliturri, FJ; Hutson, A; Johnson, M; Kader, A; Kostrewa, J; Lund, I; Mavis, C; McWhite, K; Mohr, A; Nichols, J; Przespolewski, E; Sait, SJ; Sundaram, S; Thomas, R; Torka, P; Wong, J | 1 |
| Burke, SM; Ghasemi, M; Goey, AKL; Hernandez-Ilizaliturri, FJ; Lin, LH; Mager, DE; Mavis, CK; Nichols, JR; Torka, P | 1 |
2 trial(s) available for ifosfamide and carfilzomib
| Article | Year |
|---|---|
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Prospective Studies; Rituximab | 2023 |
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Leukocytes, Mononuclear; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prospective Studies; Proteasome Endopeptidase Complex; Rituximab | 2023 |